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The STOP-Hypertension-2 study was designed to investigate how newer antihypertensive treatments (angiotensin converting enzyme (ACE) inhibitors and calcium antagonists) compare with the conventional treatments ( blockers and diuretics) shown to be eVective in STOP-Hypertension-1. 4 The study examined cardiovascular morbidity and mortality prevention. The primary aim was to assess the eVect of the diVerent treatments on mortality. A placebo group was not included for ethical reasons.
Study design
The STOP-Hypertension-2 study followed a PROBE design (prospective, randomised, open and blinded end point evaluation) and employed the same entry criteria as STOPHypertension-1: men and women aged 70-84 years with hypertension (> 180 mm Hg systolic, > 105 mm Hg diastolic, or both). A total of 6628 patients were recruited with 6614 randomised to treatment; the study period extended just over five years.
Patients were randomly assigned to treatment with one of three classes of drugs: (1) blockers, diuretics or both (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or fixed ratio hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily); (2) ACE inhibitors (enalapril 10-20 mg or lisinopril 10-20 mg daily); or (3) calcium antagonists (felodipine 2.5-5 mg or isradipine 2.5-5 mg daily). Approximately 2200 patients were assigned to each of the three treatment groups. No patients were lost to follow up in any of the groups.
The following comparisons were planned: blockers/diuretics versus ACE inhibitors; blockers/diuretics versus calcium antagonists; and ACE inhibitors versus calcium antagonists.
The study had a statistical power of 94% to detect a 25% diVerence in cardiovascular mortality between older and newer treatments.
Results
The baseline characteristics of the three groups were virtually identical as would be expected in a study with proper randomisation and suYciently large numbers. Notably, the number of patients with diabetes at baseline was virtually identical for all three groups.
A comparison of STOP-Hypertension-1 and STOP-Hypertension-2 shows that baseline patient characteristics in each study were almost identical because the same entry criteria were used. The close similarity of the two studies allows comparisons to be made between the results from STOP-Hypertension-2 and the placebo group in STOP-Hypertension-1.
BLOOD PRESSURE LOWERING
The blood pressure lowering eVects were similar in the three treatment groups. At baseline all three groups had exactly the same blood pressure of 194/98 mm Hg. By the end of the study this had been reduced to 158-159/80-81 mm Hg. It is important to note that in a substantial number of patients combined treatment was used.
ADVERSE EVENTS
Adverse events were recorded as the proportion of patients in each treatment group who, at any time during the trial, reported an event. A more thorough analysis of adverse events during STOP-Hypertension-2 will form the basis of a separate publication. The pattern of events was as expected: more shortness of breath, cold hands and feet in the blocker/ diuretic treatment group; more coughing in the ACE inhibitor group; and more swollen legs in the calcium antagonist group.
CARDIOVASCULAR EVENTS
A comparison between the results of STOPHypertension-1 and STOP-Hypertension-2 looking at major cardiovascular eventsstrokes, myocardial infarction plus other cardiovascular mortality-reveals an incidence of 55 per 1000 patient years in the placebo group; 34 in the actively treated group in STOP-Hypertension-1; and 41 in STOPHypertension-2.
The higher figures for the STOPHypertension-2 patients compared with the STOP-Hypertension-1 patients can be attributed to the longer duration of the study (five years compared with two years), which meant that patients had the chance of becoming three years older. As patients were already 76 years old on entry, the extra three years is very important in terms of cardiovascular mortality and morbidity. In addition, there was a higher prevalence of previous myocardial infarction, stroke, and diabetes mellitus in the STOPHypertension-2 study patients at baseline.
COMPARISON OF RESULTS
In STOP-Hypertension-2 there were 19.8 fatal cardiovascular events per 1000 patient years in the blocker/diuretic group; 20.5 in the ACE inhibitor group; and 19.2 in the calcium antagonist group. These are very small diVerences that are not significant (fig 1) .
There were no significant diVerences in cardiovascular mortality, all myocardial infarction, all stroke, all major cardiovascular events, total mortality, incidence of diabetes mellitus, incidence of atrial fibrillation or incidence of congestive heart failure, between the newer drugs (ACE inhibitors or calcium antagonists) and the older drugs ( blocker/diuretic). Old and new drugs did equally well in this comparison (table 1) .
ACE inhibitors versus conventional drugs
Looking at the same variables, there were no significant benefits or disadvantages of either treatment when ACE inhibitors and conventional drugs were compared. They were equally eVective in preventing events.
Calcium antagonists versus conventional treatment
There were also no significant benefits or disadvantages of choosing calcium antagonists or conventional drugs.
ACE inhibitors versus calcium antagonists
Interestingly, in the comparison of ACE inhibitors and calcium antagonists, the frequency of myocardial infarction and congestive heart failure was significantly lower in patients treated with ACE inhibitors (fig 2) . These results should, however, be interpreted with caution as 48 statistical comparisons were performed on the data from this study. With a 5% significance level, it is expected that one in 20 events will be significant by chance alone. In addition, myocardial infarction and congestive heart failure are not independent factors but are closely linked to each other. A patient who suVers a myocardial infarction has a greater risk of developing congestive heart failure.
Conclusion
All three classes of treatment were equally eVective in lowering blood pressure. In addition, all three were equally eVective in preventing cardiovascular morbidity and mortality, and were significantly better than the placebo arm in STOP-Hypertension-1.
Notably, ACE inhibitors were better than calcium antagonists in preventing myocardial infarction and congestive heart failure, but Conventional drugs ACE inhibitors Calcium antagonists 
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The reduction of blood pressure is important in elderly hypertensive patients. If blood pressure is reduced eVectively there will be a significant impact on major cardiovascular end points. The findings of this study are clearly in agreement with those of the HOT study 5 and support the recently published guidelines of the World Heath Organization-International Society of Hypertension.
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